Regeneron's Eylea snags prefilled syringe approval as Novartis rival looms
Regeneron's Eylea scored a nod for a prefilled injector application to treat four retinal conditions. (Regeneron)
Eye med Eylea has been a blockbuster sales force for Regeneron, but Novartis’ challenger brolucizumab is on the horizon. Could a new delivery option give Eylea a leg up?
That's what Regeneron's hoping. The FDA Tuesday approved a new prefilled injector for 2-milligram single doses of Eylea to treat patients with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.
The drugmaker touted the new approval as a game-changer for physicians, taking multiple preparation steps out of the original vial dose regimen. Eylea is now the only drug approved to treat four retinal diseases with a single-dose prefilled injector, although Roche's Lucentis has two prefilled injector doses that cover all four of those indications separately.
Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D
Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.
Regeneron is hoping the newest green light will help it secure its place as the top-performing wet AMD drug on the market as competitors loom.